CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: LONP2 (ImmuneEditome ID:83752)

1. Gene summary of enriched editing regions for LONP2

check button Gene summary
Gene informationGene symbol

LONP2

Gene ID

83752

GeneSynonymsLONP|LONPL|PLON|PSLON
GeneCytomap

16q12.1

GeneTypeprotein-coding
GeneDescriptionlon protease homolog 2, peroxisomal|lon protease 2|lon protease-like protein 2|peroxisomal LON protease like|peroxisomal Lon protease homolog 2
GeneModificationdate20230517
UniprotIDQ86WA8;E7EN44;H3BQ67;H3BUW8
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr16:48308726-48309281:+ENST00000285737.7ENSG00000102910.12LONP2intronicL1PB4chr16:48308726-48309281:+.alignment
chr16:48308726-48309281:+ENST00000416006.6ENSG00000102910.12LONP2intronicL1PB4chr16:48308726-48309281:+.alignment
chr16:48308726-48309281:+ENST00000535754.4ENSG00000102910.12LONP2intronicL1PB4chr16:48308726-48309281:+.alignment
chr16:48308726-48309281:+ENST00000566755.4ENSG00000102910.12LONP2intronicL1PB4chr16:48308726-48309281:+.alignment
chr16:48318043-48320089:+ENST00000285737.7ENSG00000102910.12LONP2intronicAluSx1,(TTAATA)n,AluSz,MLT1F2,AluSg4chr16:48318043-48320089:+.alignment
chr16:48318043-48320089:+ENST00000416006.6ENSG00000102910.12LONP2intronicAluSx1,(TTAATA)n,AluSz,MLT1F2,AluSg4chr16:48318043-48320089:+.alignment
chr16:48318043-48320089:+ENST00000535754.4ENSG00000102910.12LONP2intronicAluSx1,(TTAATA)n,AluSz,MLT1F2,AluSg4chr16:48318043-48320089:+.alignment
chr16:48318043-48320089:+ENST00000566755.4ENSG00000102910.12LONP2intronicAluSx1,(TTAATA)n,AluSz,MLT1F2,AluSg4chr16:48318043-48320089:+.alignment
chr16:48346657-48346936:+ENST00000285737.7ENSG00000102910.12LONP2intronicAluSz,AluJochr16:48346657-48346936:+.alignment
chr16:48346657-48346936:+ENST00000416006.6ENSG00000102910.12LONP2intronicAluSz,AluJochr16:48346657-48346936:+.alignment
chr16:48346657-48346936:+ENST00000535754.4ENSG00000102910.12LONP2intronicAluSz,AluJochr16:48346657-48346936:+.alignment
chr16:48346657-48346936:+ENST00000565867.2ENSG00000102910.12LONP2intronicAluSz,AluJochr16:48346657-48346936:+.alignment
chr16:48346657-48346936:+ENST00000566755.4ENSG00000102910.12LONP2intronicAluSz,AluJochr16:48346657-48346936:+.alignment
chr16:48352341-48354532:+ENST00000564259.1ENSG00000102910.12LONP2ncRNA_intronicAluJb,(T)n,AluSz6,AluSz,L1MB4,G-rich,MIRbchr16:48352341-48354532:+.alignment


Top

2. Tumor-specific enriched editing regions for LONP2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr16:48352341-48354532:+BRCAEER1.0478e-27image
ENSG00000102910.12,LONP2BRCAEAG1.0295e-27image
chr16:48352341-48354532:+COADEER2.0021e-16image
ENSG00000102910.12,LONP2COADEAG8.9257e-17image
chr16:48352341-48354532:+HNSCEER1.2949e-07image
ENSG00000102910.12,LONP2HNSCEAG1.2949e-07image
chr16:48352341-48354532:+KICHEER9.1288e-07image
ENSG00000102910.12,LONP2KICHEAG9.1288e-07image
chr16:48352341-48354532:+KIRPEER1.5694e-02image
ENSG00000102910.12,LONP2KIRPEAG1.6012e-02image
chr16:48352341-48354532:+LUADEER3.4441e-02image
ENSG00000102910.12,LONP2LUADEAG4.1179e-02image
chr16:48352341-48354532:+LUSCEER4.5341e-08image
ENSG00000102910.12,LONP2LUSCEAG4.5341e-08image
chr16:48352341-48354532:+STADEER2.7435e-03image
ENSG00000102910.12,LONP2STADEAG2.2434e-03image
chr16:48352341-48354532:+THCAEER6.9224e-04image
ENSG00000102910.12,LONP2THCAEAG6.7861e-04image
chr16:48352341-48354532:+UCECEER3.1257e-07image
ENSG00000102910.12,LONP2UCECEAG3.1973e-07image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000102910.12,LONP2HNSCPathEAG4.1156e-025.4327e-030.1350image
chr16:48352341-48354532:+HNSCPathEER4.1156e-025.4327e-030.1350image
ENSG00000102910.12,LONP2KIRCPathEAG1.2495e-033.0321e-030.1288image
chr16:48352341-48354532:+KIRCPathEER1.3197e-032.8263e-030.1297image
ENSG00000102910.12,LONP2THCAPathEAG5.1178e-036.4021e-040.1519image
chr16:48352341-48354532:+THCAPathEER5.4332e-036.9451e-040.1509image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for LONP2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:48352341-48354532:+TGCTEERENSG00000226976,COX6A1P20.38262.4472e-048.3749e-080.4327imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_DN
chr16:48352341-48354532:+TGCTEERENSG00000154582,TCEB10.38132.4924e-041.0201e-070.4301imageNAUH;CSTF2T;DHX9;EIF4A3;ELAVL1;FBL;IGF2BP2;MOV10;NOP56;NOP58;PTBP1;RANGAP1;TAF15;U2AF2TCEB1T_cells_CD4_memory_restingGSVA_HALLMARK_MYC_TARGETS_V2
chr16:48352341-48354532:+TGCTEERENSG00000147684,NDUFB90.36145.6528e-042.9493e-070.4157imageNAUH;CSTF2T;DHX9;EIF4A3;ELAVL1;FBL;IGF2BP2;MOV10;NOP56;NOP58;PTBP1;RANGAP1;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_MYC_TARGETS_V2
chr16:48352341-48354532:+TGCTEERENSG00000261236,BOP10.35757.0718e-047.0303e-070.4034imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MYC_TARGETS_V2
chr16:48352341-48354532:+TGCTEERENSG00000102103,PQBP10.34739.6636e-048.6664e-080.4323imageNAUH;CSTF2T;DHX9;EIF4A3;ELAVL1;FBL;IGF2BP2;MOV10;NOP56;NOP58;PTBP1;RANGAP1;TAF15;U2AF2PQBP1Macrophages_M2GSVA_HALLMARK_UV_RESPONSE_DN
chr16:48352341-48354532:+TGCTEERENSG00000224578,HNRNPA1P480.33321.8719e-037.9856e-070.4016imageNCSTF2T;ELAVL1;FBL;IGF2BP2;NOP56;TAF15NAT_cells_follicular_helperGSVA_HALLMARK_ANDROGEN_RESPONSE
chr16:48352341-48354532:+TGCTEERENSG00000077312,SNRPA0.31064.1301e-033.7733e-070.4123imageNAUH;CSTF2T;DHX9;EIF4A3;ELAVL1;FBL;IGF2BP2;MOV10;NOP56;NOP58;PTBP1;RANGAP1;TAF15;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_DNA_REPAIR

More results



Top

4. Enriched editing regions and immune related splicing for LONP2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000102910.12,LONP2
TGCTEAGIRENSG00000135953.6chr2102715839:102716041:102718189:102718334-0.32981.6655e-031.5670e-07-0.4732imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;RC3H1;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000102910.12,LONP2
TGCTEAGA5ENSG00000129933.16chr1919348888:19348938:19344251:19347366:19344251:19347370-0.30328.5249e-031.9974e-06-0.4074imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAGSVA_HALLMARK_ADIPOGENESIS
chr16:48352341-48354532:+
TGCTEERIRENSG00000196199.9chr1319668376:19670363:19670839:19670964-0.26892.3082e-027.0564e-06-0.4154imageNAUH;CSTF2T;DHX9;EIF4A3;ELAVL1;FBL;IGF2BP2;MOV10;NOP56;NOP58;PTBP1;RANGAP1;TAF15;U2AF2NADendritic_cells_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr16:48352341-48354532:+
TGCTEERIRENSG00000135953.6chr2102715839:102716041:102718189:102718334-0.32982.0405e-031.5670e-07-0.4732imageNAUH;CSTF2T;EIF4A3;ELAVL1;FBL;IGF2BP2;MOV10;NOP56;NOP58;PTBP1;RANGAP1;TAF15;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_DN
chr16:48352341-48354532:+
TGCTEERA5ENSG00000129933.16chr1919348888:19348938:19344251:19347366:19344251:19347370-0.30329.4759e-031.9974e-06-0.4074imageNAUH;CSTF2T;DHX9;EIF4A3;ELAVL1;FBL;IGF2BP2;MOV10;NOP56;NOP58;PTBP1;RANGAP1;TAF15;U2AF2NAGSVA_HALLMARK_ADIPOGENESIS
ENSG00000102910.12,LONP2
TGCTEAGIRENSG00000196199.9chr1319668376:19670363:19670839:19670964-0.26892.1550e-027.0564e-06-0.4154imageNACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184NADendritic_cells_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results



Top

5. Enriched editing regions and immune infiltration for LONP2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000102910.12,LONP2ACCEAGPlasma_cells2.4111e-020.2603image
chr16:48352341-48354532:+BLCAEERT_cells_CD4_memory_activated7.7520e-050.1963image
ENSG00000102910.12,LONP2BLCAEAGT_cells_CD4_memory_activated8.0924e-050.1958image
chr16:48352341-48354532:+BRCAEERT_cells_CD4_memory_activated4.9282e-080.1652image
ENSG00000102910.12,LONP2BRCAEAGT_cells_CD4_memory_activated4.0623e-080.1661image
chr16:48352341-48354532:+CHOLEERT_cells_CD84.1880e-03-0.4721image
ENSG00000102910.12,LONP2CHOLEAGT_cells_CD84.1880e-03-0.4721image
chr16:48352341-48354532:+COADEERMacrophages_M11.2546e-050.2605image
ENSG00000102910.12,LONP2COADEAGMacrophages_M18.2547e-040.2005image
chr16:48352341-48354532:+ESCAEERT_cells_CD82.0003e-020.1832image
ENSG00000102910.12,LONP2ESCAEAGT_cells_CD82.1755e-020.1808image
chr16:48352341-48354532:+GBMEERMacrophages_M09.0531e-05-0.3000image
ENSG00000102910.12,LONP2GBMEAGMacrophages_M09.0531e-05-0.3000image
chr16:48352341-48354532:+HNSCEERMacrophages_M01.5604e-03-0.1436image
ENSG00000102910.12,LONP2HNSCEAGMacrophages_M01.5604e-03-0.1436image
chr16:48352341-48354532:+KIRCEERT_cells_CD81.2753e-030.1645image
ENSG00000102910.12,LONP2KIRCEAGT_cells_CD81.5542e-030.1616image
chr16:48352341-48354532:+KIRPEERT_cells_follicular_helper1.2258e-040.2256image
ENSG00000102910.12,LONP2KIRPEAGT_cells_follicular_helper1.2258e-040.2256image
chr16:48352341-48354532:+LAMLEERNK_cells_activated5.4473e-030.2259image
ENSG00000102910.12,LONP2LAMLEAGNK_cells_activated7.8008e-030.2165image
chr16:48352341-48354532:+LGGEERMonocytes3.1969e-040.1562image
ENSG00000102910.12,LONP2LGGEAGMonocytes3.1969e-040.1562image
chr16:48352341-48354532:+LUADEERT_cells_CD4_memory_activated6.1689e-070.2178image
ENSG00000102910.12,LONP2LUADEAGT_cells_CD4_memory_activated1.6035e-060.2098image
chr16:48352341-48354532:+LUSCEERT_cells_CD4_memory_activated2.7969e-070.2282image
ENSG00000102910.12,LONP2LUSCEAGT_cells_CD4_memory_activated2.7969e-070.2282image
chr16:48352341-48354532:+MESOEERMacrophages_M03.2778e-030.3249image
ENSG00000102910.12,LONP2MESOEAGMacrophages_M03.2778e-030.3249image
chr16:48352341-48354532:+OVEERT_cells_CD87.9028e-060.2581image
ENSG00000102910.12,LONP2OVEAGT_cells_CD88.0790e-060.2579image
chr16:48352341-48354532:+PCPGEERNK_cells_resting1.6538e-020.1800image
ENSG00000102910.12,LONP2PCPGEAGNK_cells_resting1.6538e-020.1800image
chr16:48352341-48354532:+PRADEERT_cells_CD4_memory_resting4.5824e-040.1566image
ENSG00000102910.12,LONP2PRADEAGT_cells_CD4_memory_resting2.3672e-040.1642image
chr16:48352341-48354532:+SARCEERMast_cells_activated8.3380e-03-0.1682image
ENSG00000102910.12,LONP2SARCEAGMast_cells_activated8.3380e-03-0.1682image
chr16:48352341-48354532:+SKCMEERT_cells_CD87.4394e-030.1233image
ENSG00000102910.12,LONP2SKCMEAGT_cells_CD87.4144e-030.1234image
chr16:48318043-48320089:+STADEERT_cells_CD4_memory_resting3.2572e-02-0.3729image
chr16:48352341-48354532:+STADEERT_cells_regulatory_(Tregs)7.8346e-040.1732image
ENSG00000102910.12,LONP2STADEAGT_cells_regulatory_(Tregs)7.3554e-040.1740image
chr16:48352341-48354532:+TGCTEERT_cells_gamma_delta7.7630e-030.2234image
ENSG00000102910.12,LONP2TGCTEAGT_cells_gamma_delta7.7630e-030.2234image
chr16:48352341-48354532:+THCAEERB_cells_naive3.1536e-040.1600image
ENSG00000102910.12,LONP2THCAEAGB_cells_naive3.3203e-040.1594image
chr16:48352341-48354532:+THYMEERMacrophages_M06.0592e-030.2613image
ENSG00000102910.12,LONP2THYMEAGMacrophages_M06.0592e-030.2613image
chr16:48352341-48354532:+UVMEERMonocytes8.4570e-03-0.2925image
ENSG00000102910.12,LONP2UVMEAGMonocytes8.4570e-03-0.2925image


Top

6. Enriched editing regions and immune gene sets for LONP2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000102910.12,LONP2BLCAEAG1.9756e-080.27611.8421e-030.15535.1419e-060.22571.9866e-060.2351image
chr16:48352341-48354532:+BLCAEER1.7865e-080.27691.8896e-030.15495.0315e-060.22591.5529e-060.2375image
ENSG00000102910.12,LONP2LUADEAG1.1594e-070.23122.5095e-080.24275.2124e-050.17751.8776e-030.1368image
chr16:48352341-48354532:+LUADEER5.4110e-070.21894.0053e-080.23921.1585e-040.16928.4786e-030.1160image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr16:48352341-48354532:+BLCAGSVA_HALLMARK_UV_RESPONSE_UPEER1.2512e-070.2605image
ENSG00000102910.12,LONP2BLCAGSVA_HALLMARK_UV_RESPONSE_UPEAG2.0734e-070.2561image
chr16:48352341-48354532:+BRCAGSVA_HALLMARK_E2F_TARGETSEER2.8552e-110.2008image
ENSG00000102910.12,LONP2BRCAGSVA_HALLMARK_E2F_TARGETSEAG2.1137e-110.2020image
chr16:48352341-48354532:+CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0671e-070.3044image
ENSG00000102910.12,LONP2CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.0671e-070.3044image
ENSG00000102910.12,LONP2CHOLGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG9.3847e-03-0.4329image
chr16:48352341-48354532:+CHOLGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER9.3847e-03-0.4329image
chr16:48352341-48354532:+COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.2606e-070.3126image
ENSG00000102910.12,LONP2COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.0609e-060.2817image
ENSG00000102910.12,LONP2ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG5.3870e-030.2184image
chr16:48352341-48354532:+ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER7.2054e-030.2110image
ENSG00000102910.12,LONP2GBMGSVA_HALLMARK_APICAL_JUNCTIONEAG8.8246e-05-0.3004image
chr16:48352341-48354532:+GBMGSVA_HALLMARK_APICAL_JUNCTIONEER8.8246e-05-0.3004image
chr16:48352341-48354532:+HNSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER6.5615e-040.1545image
ENSG00000102910.12,LONP2HNSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG6.5615e-040.1545image
ENSG00000102910.12,LONP2KICHGSVA_HALLMARK_MYC_TARGETS_V1EAG8.0939e-040.4053image
chr16:48352341-48354532:+KICHGSVA_HALLMARK_MYC_TARGETS_V1EER8.0939e-040.4053image
chr16:48352341-48354532:+KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0972e-030.1666image
ENSG00000102910.12,LONP2KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.3636e-030.1635image
ENSG00000102910.12,LONP2KIRPGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.2322e-020.1204image
chr16:48352341-48354532:+KIRPGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.2322e-020.1204image
ENSG00000102910.12,LONP2LAMLGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.8844e-02-0.1916image
chr16:48352341-48354532:+LAMLGSVA_HALLMARK_SPERMATOGENESISEER2.6118e-02-0.1816image
chr16:48352341-48354532:+LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5250e-080.2434image
ENSG00000102910.12,LONP2LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5250e-080.2434image
chr16:48352341-48354532:+LIHCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.0797e-020.1142image
ENSG00000102910.12,LONP2LIHCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG9.4912e-030.1369image
chr16:48352341-48354532:+LUADGSVA_HALLMARK_E2F_TARGETSEER2.5781e-090.2589image
ENSG00000102910.12,LONP2LUADGSVA_HALLMARK_E2F_TARGETSEAG5.1455e-100.2697image
ENSG00000102910.12,LONP2LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG9.0925e-060.1978image
chr16:48352341-48354532:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.0925e-060.1978image
ENSG00000102910.12,LONP2MESOGSVA_HALLMARK_PEROXISOMEEAG3.0151e-02-0.2426image
chr16:48352341-48354532:+MESOGSVA_HALLMARK_PEROXISOMEEER3.0151e-02-0.2426image
chr16:48352341-48354532:+OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.0934e-060.2691image
ENSG00000102910.12,LONP2OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.0381e-060.2693image
chr16:48352341-48354532:+PAADGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.6271e-020.1804image
ENSG00000102910.12,LONP2PAADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.6271e-020.1804image
chr16:48352341-48354532:+PCPGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.6281e-03-0.2248image
ENSG00000102910.12,LONP2PCPGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.6281e-03-0.2248image
ENSG00000102910.12,LONP2PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0174e-080.2534image
chr16:48352341-48354532:+PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER7.9312e-090.2552image
ENSG00000102910.12,LONP2READGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.3643e-02-0.2086image
chr16:48352341-48354532:+READGSVA_HALLMARK_BILE_ACID_METABOLISMEER4.3643e-02-0.2086image
ENSG00000102910.12,LONP2SARCGSVA_HALLMARK_HEME_METABOLISMEAG2.7114e-020.1412image
chr16:48352341-48354532:+SARCGSVA_HALLMARK_HEME_METABOLISMEER2.7114e-020.1412image
chr16:48352341-48354532:+SKCMGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.8773e-040.1602image
ENSG00000102910.12,LONP2SKCMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.9728e-040.1600image
chr16:48352341-48354532:+STADGSVA_HALLMARK_UV_RESPONSE_DNEER5.8052e-06-0.2323image
ENSG00000102910.12,LONP2STADGSVA_HALLMARK_UV_RESPONSE_DNEAG3.1473e-06-0.2386image
chr16:48318043-48320089:+STADGSVA_HALLMARK_MYC_TARGETS_V2EER4.0703e-020.3582image
ENSG00000102910.12,LONP2TGCTGSVA_HALLMARK_DNA_REPAIREAG4.4248e-040.2920image
chr16:48352341-48354532:+TGCTGSVA_HALLMARK_DNA_REPAIREER4.4248e-040.2920image
chr16:48352341-48354532:+THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER7.2243e-060.1986image
ENSG00000102910.12,LONP2THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG7.9106e-060.1977image
chr16:48352341-48354532:+THYMGSVA_HALLMARK_SPERMATOGENESISEER4.2070e-02-0.1951image
ENSG00000102910.12,LONP2THYMGSVA_HALLMARK_SPERMATOGENESISEAG4.2070e-02-0.1951image
chr16:48352341-48354532:+UCECGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.3353e-020.1792image
ENSG00000102910.12,LONP2UCECGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.8232e-020.1865image
ENSG00000102910.12,LONP2UCSGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.5604e-02-0.3403image
chr16:48352341-48354532:+UCSGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.5604e-02-0.3403image
ENSG00000102910.12,LONP2UVMGSVA_HALLMARK_COAGULATIONEAG6.2800e-030.3031image
chr16:48352341-48354532:+UVMGSVA_HALLMARK_COAGULATIONEER6.2800e-030.3031image


Top

7. Enriched editing regions and drugs for LONP2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000102910.12,LONP2ACCAZD.0530EAG3.2110e-020.2478image
chr16:48352341-48354532:+BLCACisplatinEER6.2007e-11-0.3193image
ENSG00000102910.12,LONP2BLCACisplatinEAG5.7280e-11-0.3199image
chr16:48352341-48354532:+BRCAJNK.Inhibitor.VIIIEER1.5785e-06-0.1457image
ENSG00000102910.12,LONP2BRCAJNK.Inhibitor.VIIIEAG2.0698e-06-0.1440image
chr16:48352341-48354532:+CESCAZD.2281EER4.0288e-05-0.2374image
ENSG00000102910.12,LONP2CESCAZD.2281EAG4.0288e-05-0.2374image
chr16:48352341-48354532:+CHOLAZ628EER2.6736e-030.4921image
ENSG00000102910.12,LONP2CHOLAZ628EAG2.6736e-030.4921image
ENSG00000102910.12,LONP2COADCisplatinEAG1.2744e-05-0.2598image
chr16:48352341-48354532:+COADCisplatinEER1.2769e-05-0.2603image
chr16:48352341-48354532:+DLBCAZD.2281EER5.3512e-03-0.4607image
ENSG00000102910.12,LONP2DLBCAZD.2281EAG5.3512e-03-0.4607image
chr16:48352341-48354532:+ESCAFH535EER1.2732e-020.1960image
ENSG00000102910.12,LONP2ESCAFH535EAG1.0893e-020.2002image
chr16:48352341-48354532:+GBMBIBW2992EER5.1916e-05-0.3096image
ENSG00000102910.12,LONP2GBMBIBW2992EAG5.1916e-05-0.3096image
chr16:48352341-48354532:+HNSCMetforminEER3.4753e-04-0.1621image
ENSG00000102910.12,LONP2HNSCMetforminEAG3.4753e-04-0.1621image
ENSG00000102910.12,LONP2KICHEmbelinEAG1.1237e-04-0.4607image
chr16:48352341-48354532:+KICHEmbelinEER1.1237e-04-0.4607image
ENSG00000102910.12,LONP2KIRCFH535EAG1.1088e-030.1665image
chr16:48352341-48354532:+KIRCFH535EER1.0302e-030.1675image
ENSG00000102910.12,LONP2KIRPDMOGEAG6.2116e-04-0.2015image
chr16:48352341-48354532:+KIRPDMOGEER6.2116e-04-0.2015image
ENSG00000102910.12,LONP2LGGCEP.701EAG2.7469e-100.2705image
chr16:48352341-48354532:+LGGCEP.701EER2.7469e-100.2705image
chr16:48352341-48354532:+LIHCBleomycinEER2.4950e-020.1197image
ENSG00000102910.12,LONP2LIHCBleomycinEAG6.2345e-030.1457image
ENSG00000102910.12,LONP2LUADCisplatinEAG2.2971e-06-0.2067image
chr16:48352341-48354532:+LUADAS601245EER1.0017e-060.2138image
ENSG00000102910.12,LONP2LUSCImatinibEAG8.8067e-060.1981image
chr16:48352341-48354532:+LUSCImatinibEER8.8067e-060.1981image
chr16:48352341-48354532:+MESOLapatinibEER3.0090e-020.2427image
ENSG00000102910.12,LONP2MESOLapatinibEAG3.0090e-020.2427image
chr16:48352341-48354532:+OVImatinibEER1.4785e-050.2505image
ENSG00000102910.12,LONP2OVImatinibEAG1.5015e-050.2503image
ENSG00000102910.12,LONP2PAADBleomycinEAG1.2182e-040.2848image
chr16:48352341-48354532:+PAADBleomycinEER1.2182e-040.2848image
chr16:48352341-48354532:+PCPGJNK.Inhibitor.VIIIEER2.0200e-02-0.1745image
ENSG00000102910.12,LONP2PCPGJNK.Inhibitor.VIIIEAG2.0200e-02-0.1745image
chr16:48352341-48354532:+PRADMetforminEER2.5267e-130.3204image
ENSG00000102910.12,LONP2PRADMetforminEAG9.8099e-140.3256image
ENSG00000102910.12,LONP2READCyclopamineEAG2.8821e-04-0.3677image
chr16:48352341-48354532:+READCyclopamineEER2.8821e-04-0.3677image
chr16:48352341-48354532:+SARCBleomycinEER3.5712e-040.2263image
ENSG00000102910.12,LONP2SARCBleomycinEAG3.5712e-040.2263image
chr16:48352341-48354532:+SKCMJNK.9LEER3.9692e-04-0.1627image
ENSG00000102910.12,LONP2SKCMJNK.9LEAG4.0141e-04-0.1626image
ENSG00000102910.12,LONP2STADAZD6482EAG9.3041e-050.2010image
chr16:48352341-48354532:+STADAZD6482EER1.0121e-040.1999image
chr16:48346657-48346936:+STADDoxorubicinEER2.4606e-030.6382image
chr16:48318043-48320089:+STADATRAEER5.9728e-030.4684image
ENSG00000102910.12,LONP2TGCTAZD6482EAG2.0549e-040.3077image
chr16:48352341-48354532:+TGCTAZD6482EER2.0549e-040.3077image
chr16:48352341-48354532:+THCACytarabineEER1.1398e-090.2672image
ENSG00000102910.12,LONP2THCACytarabineEAG1.4861e-090.2654image
chr16:48352341-48354532:+THYMAZD6244EER1.6955e-03-0.2973image
ENSG00000102910.12,LONP2THYMAZD6244EAG1.6955e-03-0.2973image
chr16:48352341-48354532:+UCECJNK.9LEER4.8546e-060.3525image
ENSG00000102910.12,LONP2UCECJNK.9LEAG5.0414e-060.3519image
ENSG00000102910.12,LONP2UVMCGP.60474EAG3.1210e-04-0.3929image
chr16:48352341-48354532:+UVMCGP.60474EER3.1210e-04-0.3929image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType